Published in Clin Cancer Res on September 15, 2006
Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther (2013) 3.05
A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther (2013) 1.80
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol (2010) 1.33
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst (2011) 1.12
Global variation in CYP2C8-CYP2C9 functional haplotypes. Pharmacogenomics J (2009) 1.09
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin Proc (2014) 0.99
Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther (2014) 0.95
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2012) 0.91
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res (2010) 0.87
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. Pak J Med Sci (2007) 0.85
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) (2013) 0.81
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? EPMA J (2010) 0.80
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer (2012) 0.77
Clinical management of localized colon cancer with capecitabine. Clin Med Insights Oncol (2012) 0.77
A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist (2014) 0.77
Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient. Therap Adv Gastroenterol (2016) 0.75
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2013) 0.75
A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease. J Parkinsons Dis (2012) 0.75
Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer. J Oncopathol (2013) 0.75
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer (2017) 0.75
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics (2003) 2.89
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39
Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS One (2009) 2.21
Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs (2009) 1.99
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res (2005) 1.98
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (2006) 1.78
In utero exposure to bisphenol A shifts the window of susceptibility for mammary carcinogenesis in the rat. Environ Health Perspect (2010) 1.75
Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol (2003) 1.70
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther (2007) 1.68
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis (2010) 1.61
Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem (2002) 1.54
Waist circumference values are increasing beyond those expected from BMI increases. Obesity (Silver Spring) (2007) 1.54
Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg (2005) 1.47
Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg (2006) 1.46
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43
Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res (2002) 1.35
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2009) 1.34
Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis (2006) 1.32
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28
Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys (2008) 1.27
IFTA-2 is a conserved cilia protein involved in pathways regulating longevity and dauer formation in Caenorhabditis elegans. J Cell Sci (2006) 1.24
Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res (2013) 1.24
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol (2005) 1.23
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther (2007) 1.19
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (2006) 1.12
Predictors of bacterial vaginosis in adolescent women who douche. Sex Transm Dis (2004) 1.12
Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol (2011) 1.11
Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol (2008) 1.08
The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc (2010) 1.08
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol (2004) 1.07
Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res (2012) 1.07
Aripiprazole (Otsuka Pharmaceutical Co). Curr Opin Investig Drugs (2002) 1.06
Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06
Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res (2005) 1.04
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J (2007) 1.04
Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02
Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02
DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol (2006) 1.02
Light-intensity activity attenuates functional decline in older cancer survivors. Med Sci Sports Exerc (2014) 1.02
Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics (2002) 1.01
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res (2006) 1.00
Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg (2007) 1.00
Peripheral neuropathy associated with capecitabine. Anticancer Drugs (2004) 0.99
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res (2004) 0.99
Partnership concurrency status and condom use among women diagnosed with Trichomonas vaginalis. Womens Health Issues (2008) 0.99
Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99
Factors associated with intention to vaccinate a daughter against HPV: a statewide survey in Alabama. J Pediatr Adolesc Gynecol (2011) 0.98
Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol (2002) 0.98
Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res (2014) 0.98
Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98
Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope (2010) 0.97
Effect of diet with and without exercise training on markers of inflammation and fat distribution in overweight women. Obesity (Silver Spring) (2010) 0.96
Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96
IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96
Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol (2006) 0.94
The impact of cost on the availability of fruits and vegetables in the homes of schoolchildren in Birmingham, Alabama. Am J Public Health (2006) 0.94
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93
Outcomes following temporal bone resection. Laryngoscope (2010) 0.93
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol (2012) 0.93
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol (2002) 0.92
Induction of NQO1 in cancer cells. Methods Enzymol (2004) 0.92
Association of Mobiluncus curtisii with recurrence of bacterial vaginosis. Sex Transm Dis (2008) 0.91
Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther (2002) 0.91
FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91